The quest for personalized B-cell depletion therapy in rheumatic disease
Although B cell depletion therapy (BCDT) is now a well-accepted therapeutic option in autoimmune rheumatic disease, a significant proportion of patients remain resistant to therapy. .19pt?>A more challenging clinical problem is the high rate of relapse after B cell reconstitution, as well as the...
Saved in:
Published in | Arthritis research & therapy Vol. 16; no. 3; p. 116 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
01.01.2014
BioMed Central |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Although B cell depletion therapy (BCDT) is now a well-accepted therapeutic option in autoimmune rheumatic disease, a significant proportion of patients remain resistant to therapy. .19pt?>A more challenging clinical problem is the high rate of relapse after B cell reconstitution, as well as the difficulty in predicting the exact timing of that relapse. In this article, we consider the immunological mechanisms that may account for the heterogeneity of clinical response to BCDT. Understanding how BCDT alters the balance between different B cell subsets, some pathogenic and some regulatory, may help us correctly target BCDT to the right patients, and thereby improve treatment responses in rheumatic disease. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1478-6354 1478-6362 1478-6354 |
DOI: | 10.1186/ar4595 |